Conatus Pharmaceuticals (CNAT) Emricasan Phase 2 Liver Cirrhosis Trial Shows Statistically Significant Reduction in cCK18
Tweet Send to a Friend
Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced that the three-month, double-blind, placebo-controlled stage of the company’s multicenter Phase 2 Liver ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
